2-DG is yet another addition to our COVID-19 portfolio that already covers the full spectrum of mild to moderate and severe conditions and ... Jun 28
In fewer than twelve months, AstraZeneca has worked extremely hard to develop an effective vaccine at no profit and is the second-largest supplier to ... Jun 18
It is important to note that tofacitinib has not been approved or authorized for use by any regulatory authority worldwide for the treatment of COVID-... Jun 17
Real-world data demonstrated 92% vaccine effectiveness against hospitalisations due to the Delta variant ... Jun 16
Molnupiravir, the antiviral drug was initially developed for the treatment of influenza and is repurposed to completely suppress the COVID virus transmission within 24 hours.... Jun 11
These doses are part of Pfizer and BioNTech’s previously announced pledge to provide two billion doses of the COVID-19 vaccine to low- and ... Jun 10
The treatment reduces mortality, shortens hospital stay and reduces the chances of people needing invasive mechanical ventilators... Feb 12
While the pseudovirus system used is a surrogate for authentic SARS-CoV-2, previous studies have shown excellent concordance between pseudotype neutralization and SARS-CoV-... Jan 21
... Jan 16
Vir Biotechnology, Inc. and GlaxoSmithKline plc today announced an agreement with the U.K.-based AGILE initiative to evaluate VIR-7832 in patients with mild ... Jan 12
AstraZeneca’s COVID-19 vaccine has been granted emergency use authorization in India as well as Argentina, Dominican Republic, El Salvador, Mexico and Morocco for ... Jan 07
... Dec 24
... Dec 23
... Dec 22
ACTIV-3 is an NIH-led public-private partnership designed to accelerate the development of the most promising treatments and vaccine candidates for COVID-19.... Dec 18
CIPtest is a reliable high-performing kit that has been validated and approved by ICMR.... Dec 16
Interim analysis showed vaccine is effective at preventing COVID-19, with no severe cases and no hospitalizations more than 21 days after first injection... Dec 09
Rhizen today announced the approval of IND application by the U.S. FDA to study its oral DHODH inhibitor for SARS-CoV-2 infection.... Dec 04
This will be a multicenter and randomized controlled study, which will include a safety and immunogenicity study.... Dec 02
Hon'ble Prime Minister's leadership vision, in-depth understanding and knowledge of the facts guided us in facilitating the interactions and discussions on the ... Nov 30
The oral antiviral medication Favipiravir, which prevents the replication phase of the virus life-cycle, leads to significant improvement in clinical cure in patients with ... Nov 23
Meaningful new therapeutic options are desperately needed for possibly millions of people around the world who will develop severe or critical COVID-19 disease... Nov 23
Positive high-level results from an interim analysis of clinical trials of AZD1222 in the UK and Brazil showed the vaccine was highly effective in ... Nov 23
CALAVI did not meet the primary endpoint of increasing the proportion of patients who remained alive and free of respiratory failure... Nov 12
-Advertisements-
.jpeg)
Monday, October 07, 2024
.jpg)
.jpg)